Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Medical Center Alkmaar.
Recruitment status was:  Not yet recruiting
Leiden University Medical Center
Universiteit van Amsterdam
Information provided by:
Medical Center Alkmaar Identifier:
First received: March 5, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Pulmonary Emphysema
Drug: Doxycycline
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.

Resource links provided by NLM:

Further study details as provided by Medical Center Alkmaar:

Primary Outcome Measures:
  • myeloperoxidase in induced sputum [ Time Frame: 3 weeks ]

Secondary Outcome Measures:
  • MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum. [ Time Frame: 3 weeks ]
  • Lung function (FEV1) [ Time Frame: 3 weeks ]
  • Symptom scores [ Time Frame: 3 weeks ]

Estimated Enrollment: 30
Study Start Date: April 2009
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Doxycycline 100mg daily
Drug: Doxycycline
Doxycycline tablets, 100mg daily
Placebo Comparator: 2
Drug: Placebo
Placebo tablets 100mg

Detailed Description:


COPD is a disease characterized by chronic inflammation and irreversible airway obstruction. Chronic inflammation lead to degradation of extracellular matrix and hereby destruction of lung parenchyma. Tetracyclines are known for their anti-inflammatory properties in diseases such as rheumatoid arthritis.


To assess the effect of doxycycline on markers of neutrophilic inflammation and proteolytic activity in induced sputum of stable GOLD II and III COPD patients.

Study population:

Thirty patients with stable GOLD II COPD.


Placebo versus doxycycline in randomised design.


Ages Eligible for Study:   41 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • GOLD II or III COPD (GOLD II: FEV1/FVC < 70%; 50% < FEV1 < 80% predicted, GOLD III: FEV1/FVC < 70%; 30% < FEV1 < 50% predicted ).
  • Stable disease (no exacerbations in the last 3 months).
  • Age > 40 yrs.
  • Written informed consent.

Exclusion Criteria:

  • Infections and/or use of antibiotics in the last month.
  • Bacterial colonization of the airways, proven by sputum cultures or broncho-alveolar lavage (BAL).
  • Allergy for tetracyclines or a history of substantial side-effects.
  • Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung cancer, bronchiectasis).
  • Acute exacerbation of COPD as defined by Anthonisen et al. [10].
  • Signs and/or symptoms of a current respiratory or non-respiratory infection.
  • Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the last month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00857038

Contact: Wim G Boersma, MD 0031725482750

Medical Center Alkmaar Not yet recruiting
Alkmaar, Noord-Holland, Netherlands, 1815JD
Contact: Wim G Boersma, MD    0031725482750   
Sponsors and Collaborators
Medical Center Alkmaar
Leiden University Medical Center
Universiteit van Amsterdam
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Boersma, MD, PhD, Medical Center Alkmaar Identifier: NCT00857038     History of Changes
Other Study ID Numbers: M07-046
Study First Received: March 5, 2009
Last Updated: March 5, 2009

Keywords provided by Medical Center Alkmaar:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Pulmonary Emphysema
Respiratory Tract Diseases
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on April 28, 2017